Key Points
- Insider sale: Terilyn Monroe sold 3,832 shares on April 6 at an average of $92.68 (≈$355,150), reducing her position by 15.44% to 20,990 shares; the trade was executed under a pre-arranged Rule 10b5-1 plan and disclosed to the SEC.
- Market movement and valuation: GH shares opened around $93.30 and were reported up about 4.1%; the company has a market cap of roughly $12.24 billion and a 12‑month trading range of $36.36–$120.74.
- Fundamentals and analyst views: Guardant missed quarterly EPS (-$0.50 vs. -$0.43) but revenue rose 39.4% to $281.3M, and analysts hold a "Moderate Buy" consensus with an average target near $125.95 after multiple target increases.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 3,832 shares of Guardant Health stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the sale, the insider owned 20,990 shares of the company's stock, valued at approximately $1,945,353.20. This trade represents a 15.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Trading Up 4.1%
Shares of GH opened at $93.30 on Wednesday. The company has a market cap of $12.24 billion, a PE ratio of -28.19 and a beta of 1.64. The stock has a 50-day moving average price of $96.14 and a 200-day moving average price of $93.40. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $120.74.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analysts' expectations of $269.74 million. The company's revenue was up 39.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) EPS. As a group, analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts recently weighed in on the company. Raymond James Financial restated an "outperform" rating and issued a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. Robert W. Baird assumed coverage on Guardant Health in a research report on Tuesday, February 17th. They issued an "outperform" rating and a $120.00 target price for the company. BTIG Research boosted their target price on Guardant Health from $140.00 to $145.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. JPMorgan Chase & Co. boosted their target price on Guardant Health from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Friday, February 20th. Finally, Stifel Nicolaus boosted their target price on Guardant Health from $120.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Twenty investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $125.95.
Check Out Our Latest Analysis on Guardant Health
Hedge Funds Weigh In On Guardant Health
A number of large investors have recently bought and sold shares of the stock. Allworth Financial LP increased its stake in Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company's stock worth $53,000 after purchasing an additional 138 shares during the period. Eastern Bank increased its stake in Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company's stock worth $221,000 after purchasing an additional 139 shares during the period. TD Waterhouse Canada Inc. increased its stake in Guardant Health by 3.2% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company's stock worth $306,000 after purchasing an additional 151 shares during the period. Xponance LLC increased its stake in Guardant Health by 2.1% in the 4th quarter. Xponance LLC now owns 9,630 shares of the company's stock worth $984,000 after purchasing an additional 199 shares during the period. Finally, Danske Bank A S increased its stake in Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company's stock worth $123,000 after purchasing an additional 200 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
